Matthew H. Kulke - Concepedia

Author

Matthew H. Kulke

Also Known As

David Bushnell, Elise Kohn, Hollis, Donna R., Jaffe, Deborah, Kulke, M.H., Kulke, Matthew H, M H Kulke, M Kulke, M. H Kulke, M. H. Kulke

416

Publications

27.5K

Citations

H-Index

118

Concepts

All Affiliations

Dana-Farber Cancer Institute Harvard University Massachusetts General Hospital Brigham and Women's Hospital The University of Texas MD Anderson Cancer Center

About

Matthew H. Kulke is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	47	78	10.6K
2	Health Sciences	15	20	2.1K
3	Engineering	4	4	243
4	Public Health	3	3	584
5	Biology	1	1	44

Matthew H. Kulke

179

Publications

22.7K

Citations

H-Index

Page 1

	Year	Citations
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin, New England Journal of Medicine	2017	3K
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study James C. Yao, Nicola Fazio, Simron Singh, The Lancet OncologyGastrointestinal OncologyMedicinePathologyCancer Treatment	2015	1.2K
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial James C. Yao, Catherine Lombard‐Bohas, Éric Baudin, Journal of Clinical Oncology Octreotide LarSurgical OncologyPancreatic CancerPhase Ii TrialGastrointestinal Oncology	2009	648
Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors Matthew H. Kulke, Heinz‐Josef Lenz, Neal J. Meropol, Journal of Clinical Oncology	2008	618
Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors Pamela L. Kunz, Diane Reidy‐Lagunes, Lowell Anthony, Pancreas Tumor BiologyGliomaMedicineNeuroendocrine DisorderPathology	2013	582
NANETS Treatment Guidelines Matthew H. Kulke, Lowell Anthony, David Bushnell, Pancreas Surgical OncologyOncologyPancreatic CancerGastrointestinal OncologySymptomatic Treatment	2010	569
Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors Matthew H. Kulke, Keith Stuart, Peter C. Enzinger, Journal of Clinical Oncology	2006	512
Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer Matthew B. Yurgelun, Matthew H. Kulke, Charles S. Fuchs, Journal of Clinical Oncology Crc CareSomatic VariantCancer EpidemiologyCancer RiskMedicine	2017	502
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018 Manisha H. Shah, Whitney Goldner, Þorvarður R. Hálfdánarson, Journal of the National Comprehensive Cancer Network Endocrine OncologySurgical OncologyTumoral PathologyMedicinePrimary Net	2018	388
<i>O</i> 6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors Matthew H. Kulke, Jason L. Hornick, Christine Frauenhoffer, Clinical Cancer Research	2008	379

Page 1